Search Results - Clinical Specialty > Oncology

13 Results Sort By:
Novel Capsazepine Analogs to Treat Cancer
Novel compounds have been developed based upon the capsazepine pharmacophore that are effective in halting tumor cell proliferation in vitro and in vivo. Capsazepine is a known, off-patent, analog of Capsaicin that has been proposed and studied as a TRPV1 antagonist for treatment of pain. Although Capsazepine has been proposed for alleviation of p...
Published: 8/23/2018   |   Inventor(s): Cara Gonzales, Stanton McHardy
Category(s): Clinical Specialty > Oncology, Therapeutics > Small Molecule
Inducing Chemotherapeutic Sensitivity in Hyper-Transcription Diseases
This discovery is a method for the induction of sensitivity in tumor cells to a synergistic combination of PARP1 and ATR inhibition. It is applicable to hyper-transcription diseases , primarily cancers, including: Ewing sarcoma, acute myeloid leukemia, breast cancer, myelodysplastic syndrome, and possibly even Alzheimers and ALS. Background:Modern ...
Published: 8/23/2018   |   Inventor(s): Alexander Bishop, Aparna Gorthi, Carolina Romero, Liesl Lawrence
Category(s): Clinical Specialty > Hematology, Clinical Specialty > Oncology, Clinical Specialty > Orthopedics, Diagnostics > Biomarkers, Diagnostics > Assay
Novel Compounds to Inhibit Cancer, Cancer Metastasis, and Autoimmune Diseases
Several candidate small molecules have been discovered that show dose-dependent anti-cancer effects in vitro. These compounds each have one of the following characteristics: (1) non-hydrolyzable ATP analog or (2) adenosine receptor antagonist. Testing of these compounds has demonstrated successful inhibition of cancer cell migration. Additionally...
Published: 5/22/2018   |   Inventor(s): Jean Jiang
Category(s): Clinical Specialty > Immunology, Clinical Specialty > Oncology, Therapeutics > Small Molecule
Intravenous Tramadol for Treatment of anti-NMDA Encephalitis
The invention is a combinatorial therapy used to enhance the efficacy of plasma exchange (PLEX) in treating patients with anti-NMDAR encephalitis. This treatment regimen would treat both the psychiatric and immunological manifestations of this disorder and substantially lower the patients’ recovery periods. Background:Anti-NMDAR encephalitis ...
Published: 4/20/2018   |   Inventor(s): Ali Seifi
Category(s): Therapeutics > Small Molecule, Clinical Specialty > Neurology, Clinical Specialty > Oncology, Clinical Specialty > Immunology
Combination of DHA and HDACIs in treating Prostate Cancer
The disclosed invention is a proposed combination therapy to treat prostate cancer, especially prostate cancer patients with biochemical recurrence (BCR). The combination therapy is composed of UTH1, a fatty acid compound with Generally Recognized As Safe (GRAS) status, and Valproic Acid (VPA), a generic drug with clinical use since 1963 as a mood ...
Published: 3/9/2018   |   Inventor(s): Wasim Chowdhury, Ronald Rodriguez, Md Rahman
Category(s): Therapeutics > Small Molecule, Clinical Specialty > Oncology, Clinical Specialty > Reproductive Health, Clinical Specialty > Urology
ANGPTL4 as prognostic marker for bladder cancer
Researchers at UT Health SA have discovered a less invasive method to monitor for recurrence of bladder cancer. Using Angiopoietin-like 4 protein (ANGPTL4) as a prognostic indicator, clinicians would be able to use a urine sample to monitor the likelihood of recurrence of non-muscle invasive bladder cancer. Background:Non-muscle invasive bladder ca...
Published: 3/6/2018   |   Inventor(s): Rita Ghosh, Roble Bedolla, Eduardo Cardenas, Neelam Mukherjee, Tiffani Houston
Category(s): Diagnostics > Biomarkers, Clinical Specialty > Oncology, Clinical Specialty > Urology
Non-Hydrolysable ATP for Treatment of Cancer
UT Health San Antonio scientists have discovered that non-hydrolysable forms of ATP reduce cell migration and proliferation in metastatic cancers.Background:ATP (adenosine 5'-triphosphate) has been proposed as a therapeutic agent to improve nutritional status, reduce fatigue, reduce side effects associated with chemotherapy, and promote overall qua...
Published: 4/16/2015   |   Inventor(s): Jean Jiang, Jade Zifei Zhou
Category(s): Therapeutics > Biologics, Clinical Specialty > Oncology
miRNAs for Treatment of Drug Resistant Breast Cancers
Researchers at UT Health San Antonio have identified a microRNA that can uniquely sensitize drug-resistant, triple-negative breast cancer to chemotherapy drugs such as paclitaxel, providing a novel and potent potential therapeutic approach with lower toxicity and reduced side effects.Background:Disease-free survival is short-lived for women with tr...
Published: 4/10/2015   |   Inventor(s): Manjeet Rao, J. Saadi Imam, Behyar Zoghi, Yao-Fu-Chang, Panneerdoss Subbarayalu
Category(s): Life Sciences Research Tools > Biomarkers, Therapeutics > Biologics, Clinical Specialty > Oncology, Clinical Specialty > Women's Health
Allosteric Proteasome Inhibitors for Treatment of Cancer
UT Health San Antonio scientists have discovered novel small-molecule compounds that have allosteric signaling activity to modulate proteasome catalytic activity. The allosteric proteasome inhibitors can be used alone or in combination with existing competitive proteasome inhibitors for the treatment of cancer. Studies of combination treatment de...
Published: 4/10/2015   |   Inventor(s): Pawel Osmulski, Maria Gaczynska
Category(s): Therapeutics > Small Molecule, Clinical Specialty > Oncology
Novel Inhibitors of Proto-Oncogene PELP1
Novel peptide inhibitors that disrupts the functional interactions of oncogenic protein PELP1 have been discovered by researchers at UT Health San Antonio. These inhibitors can be used for treatment of cancers that are characterized as over-expressing PELP1.Background:PELP1 overexpression, noted in many hormone-related cancers such as breast, prost...
Published: 4/10/2015   |   Inventor(s): Ratna Vadlamudi, Monica Mann, Samaya Krishnan, Gangadhara Sareddy
Category(s): Therapeutics > Small Molecule, Clinical Specialty > Oncology
1 2